Dr. David M. Spector, MD | Davenport ...

Dr. David M. Spector

Claim this profile

Genesis Cancer Care Institute

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
39 drugs studied

About David M. Spector

Education:

  • Earned an MD from the University of Iowa Carver College of Medicine in 1987.

Experience:

  • Currently a Radiation Oncologist at Genesis Cancer Care Institute.
  • Board Certified in Radiation Oncology by the American Board of Radiology.
  • Completed both a Fellowship and Residency in Radiation Oncology at the University of California, San Francisco.
  • Undertook an Internship in Internal Medicine at the University of Iowa Hospitals and Clinics.

Area of expertise

1Lung Cancer
David M. Spector has run 8 trials for Lung Cancer. Some of their research focus areas include:
Stage III
Stage II
Stage I
2Non-Small Cell Lung Cancer
David M. Spector has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage III
Stage II
Stage I

Affiliated Hospitals

Image of trial facility.
Genesis Cancer Care Institute
Image of trial facility.
Genesis Cancer Center - Silvis

Clinical Trials David M. Spector is currently running

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

More about David M. Spector

Clinical Trial Related5 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments David M. Spector has experience with
  • Paclitaxel
  • Carboplatin
  • Pembrolizumab
  • Gemcitabine Hydrochloride
  • Leucovorin Calcium
  • Fluorouracil

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does David M. Spector specialize in?
Is David M. Spector currently recruiting for clinical trials?
Are there any treatments that David M. Spector has studied deeply?
What is the best way to schedule an appointment with David M. Spector?
What is the office address of David M. Spector?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security